Небулайзерная терапия обструктивных заболеваний легких

1. Global Initiative for Asthma. Global strategy for asthma management and prevention. The 2009 report is available on: www. ginasthma.org.
2. Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. The 2009 report is available on: www.goldcopd.com.
3. Bateman ED, Hurd SS, Barnes PJ et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31: 143–78.
4. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469–78.
5. Buist AS, McBurnie MA, Vollmer WM et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741–50.
6. Cochrane MG, Bala MV, Downs KE et al. Inhaled corticosteroids for asthma therapy. Patient compliance, devices, and inhalation technique. Chest 2000; 117: 542–50.
7. Huchon G. Metered dose inhalers part and present: advantages and limitations. Eur Respir Rev 1997; 7: 41, 26–8.
8. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002; 96: 293–304.
9. Авдеев С.Н. Устройства доставки ингаляционных препаратов, используемые при терапии заболеваний дыхательных путей. Рус. мед. журн. 2002; 10 (5): 255–61.
10. Boe J, Dennis JH, O'Driscoll BR et al. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J 2001; 18: 228–42.
11. Dennis JH. A review of issues relating to nebulizer standards. J Aerosol Med 1998; 11: 73–9.
12. Hess DR. Nebulizers: Principles and performance. Respir Care 2000; 45: 609–22.
13. Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care 2002; 47: 1406–18.
14. Siefkin AD. Optimal pharmacologic treatment of the critically ill patients with obstructive airways disease. Am J Med 1996; 100 (Suppl. 1A): 54S–61S.
15. Авдеев С.Н. Небулайзерная терапия суспензией Пульмикорта: место в лечении заболеваний дыхательных путей. Методическое пособие для врачей. 2-е изд., перераб. и доп. М., 2008.
16. Ward MJ. Nebulizers for asthma. Thorax 1997; 52 (Suppl. 2): S45–S48.
17. National Asthma Education Program. Expert Panel Report III: Guidelines for the Diagnosis and Management of Asthma. 2007. In: National Institutes of Health. Bethesda, MD: 2007.
18. Ziment I. The β2-agonist controversy. Chest 1995; 107 (Suppl.): 198S–205S.
19. Ziment I. Beta-adrenergic agonist toxicity: less a problem, more of a perception. Chest 1993; 103: 1591–7.
20. Bryant DH. Nebulized ipratropium bromide in the treatment of acute asthma. Chest 1985; 88: 24–9.
21. Ind PW, Dixon CMS, Fuller RW, Barnes PJ. Anticholinergic blockage of beta-blocker-induced bronchoconstriction. Am Rev Respir Dis 1989; 139: 1390–4.
22. Brophy C, Ahmed B, Bayston S et al. How long should Atrovent be given in acute asthma? Thorax 1998; 53: 363–7.
23. British Thoracic Society Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2008; 63 (Suppl. 4): iv1–iv121.
24. Whyte KF, Gould GA, Jeffrey AA et al. Dose of nebulized ipratropium bromide in acute severe asthma. Respir Med 1991; 85: 517–20.
25. O'Driscoll BR, Taylor RJ, Horsley MG et al: Nebulized salbutamol with and without ipratropium bromide in acute airflow obstruction. Lancet 1989; I: 1418–20.
26. Rebuck AS, Chapman KR, Abboud R et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med 1987; 82: 59–64.
27. Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Arch Intern Med 1999; 159: 156–160.
28. Stoodley RG, Aaron SD, Dales RE. The role of ipratropium bromide in the emergency management of acute asthma exacerbation: a meta-analysis of randomized clinical trials. Ann Emerg Med 1999; 34: 8–18.
29. Ward MJ. The role of anticholinergic drugs in acute asthma. In: Anticholinergic therapy in obstructive airways disease. Ed. Gross NJ. London: Franclin Scientific Publications, 1993; p. 155–68.
30. Lanes SF, Garrett JE, Wentworth CE et al. The effect of adding ipratropium bromide to salbutamol in the treatment of acute asthma. A pooled analysis of three trials. Chest 1998; 114: 365–72.
31. Garrett JE, Town GI, Rodwell P, Kelly AM. Nebulized salbutamol with and without ipratropium bromide in the treatment of acute asthma. J Allergy Clin Immunol 1997; 100: 165–70.
32. Pedersen S, O’Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997; 52 (Suppl. 39): 1–34.
33. Rodrigo GJ. Rapid effects of inhaled corticosteroids in acute asthma. An evidence-based evaluation. Chest 2006; 130; 1301–11.
34. Авдеев С.Н., Жестков А.В., Лещенко И.В. и др. Небулизированный будесонид при тяжелом обострении бронхиальной астмы: сравнение с системными стероидами. Мультицентровое рандомизированное контролируемое исследование. Пульмонология. 2006; 4: 58–67.
35. Parker CM, Voduc N, Aaron SD et al. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J 2005; 26: 420–8.
36. Rodríguez-Roisin R. COPD exacerbations: management. Thorax 2006; 61: 535–44.
37. McCrory DC, Brown CD. Anticholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2003, Issue 1. Art. No.: CD003900. DOI: 10.1002/14651858. CD003900.
38. Cuvelier A, Muir JF pour le groupe multicentrique. Apport de la nébulisation dans les exacerbations des bronchopneumopathies chroniques obstructives: place des anticholinergiques. Ann Fr Anesth Réanim 1998; 17 (Suppl. 2): 48–51.
39. Karpel JP. The use of anticholinergic drugs in acute exacerbations of chronic obstructive pulmonary disease. In: Gross NJ, ed. Anticholinergic Therapy in Obstructive Airways Disease. London: Franklin Scientic Publications, 1993; p. 145–54.
40. Bach PB, Brown C, Gelfand SE, McCrory DC. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 2001; 134: 600–20.
41. Nair S, Thomas E, Pearson SB, Henry MT. A randomized controlled trial to assess the optimal dose and effect of nebulized albuterol in acute exacerbations of COPD. Chest 2005; 128: 48–54.
42. Siafakas NM, Vermeire P, Pride NB et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8: 1398–420.
43. Gross NJ, Petty TL, Friedman M et al. Dose response to ipratropium as a nebulised solution in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 139: 1188–91.
44. O’Donnell, Aaron S, Bourbeau J et al. State of the Art Compendium: Canadian Thoracic Society DE recommendations for the management of chronic obstructive pulmonary disease. Can Respir J 2004; 11 (Suppl. B): 7B–59B.
45. COPD Guideline Working Group of the South African Thoracic Society. Guideline for the Management of Chronic Obstructive Pulmonary Disease (COPD): 2004 Revision. S Afr Med J 2004; 94: 559–75.
46. Willaert W, Daenen M, Bornans P et al. What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Eur Respir J 2002; 19: 928–35.
47. Guerin C, Chevre A, Dessirier P et al. Inhaled fenoterol-ipratropium bromide in mechanically ventilated patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1036–42.
48. Авдеев С.Н., Нуралиева Г.С., Батын С.З. и др. Эффективность комбинированной терапии ингаляционными 
β2-агонистами и антихолинергическими препаратами при тяжелом обострении хронической обструктивной болезни легких: рандомизированное контролируемое исследование. Пульмонология. 2007; 3: 56–65.
49. Авдеев С.Н., Суточникова О.А., Белевский А.С., Чучалин А.Г. Применение небулизированного будесонида при тяжелом обострении хронической обструктивной болезни легких. Рандомизированное контролируемое исследование. Пульмонология. 2003; №5: 81–8.
50. Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G. The role of nebulised budesonide in the treatment of acute exacerbations of COPD. Eur Respir J 2007; 30: 399–400.
51. Baker EH, Janaway CH, Philips BJ et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 2006; 61: 284–9.
52. Dolovich MB, Ahrens RC, Hess DR et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines. Chest 2005; 127: 335–71.
53. British Thoracic Society Nebuliser Project Group. Current best practice for nebuliser treatment. Thorax 1997; 52 (Suppl. 2): S1–S24.
54. O’Driscoll BR, Kay EA, Taylor RJ et al. A long-term prospective assessment of home nebulizer treatment. Respir Med 1992; 86: 317–25.
55. Tashkin D, Klein G, Colman SS et al. Comparing COPD treatment: nebulizer, metered dose inhaler and concomitant therapy. Am J Med 2007; 120: 435–41.
56. Gawchik SM. Successful treatment of previously uncontrolled adult asthma with budesonide inhalation suspension: five-year case histories. Ann Pharmacother 2007; 41: 1728–33.
57. Marcus P, Oppenheimer EA, Patel PA et al. Use of nebulized inhaled corticosteroids among older adult patients: an assessment of outcomes. Ann Allergy Asthma Immunol 2006; 96: 736–43.

С.Н.Авдеев 

ФГУ НИИ пульмонологии ФМБА России, Москва